Literature DB >> 26991969

ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.

Andrea K Steck1, Alexandra Fouts1, Dongmei Miao1, Zhiyuan Zhao1, Fran Dong1, Jay Sosenko2, Peter Gottlieb1, Marian J Rewers1, Liping Yu1.   

Abstract

BACKGROUND: Relatives with single positive islet autoantibodies have a much lower risk of progression to diabetes than those with multiple autoantibodies.
MATERIALS AND METHODS: TrialNet subjects positive for single autoantibody to insulin (mIAA) (n = 50) or single autoantibody to glutamic acid decarboxylase (GADA) (n = 50) were analyzed using new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at their initial visit and longitudinally over time. Affinity assays were performed on a subset of single autoantibody-positive subjects at initial and most recent visits.
RESULTS: After a mean follow-up of 5.3 years, 20 subjects developed type 1 diabetes. Among either single GADA or single mIAA subjects, those who were positive in the ECL assay showed higher affinity at the initial visit, and affinity results stayed consistent over time. No converting events from low to high or high to low affinity were seen over time.
CONCLUSIONS: Confirmed positivity for ECL is associated with high affinity and can help staging of risk for type 1 diabetes in single autoantibody-positive subjects.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26991969      PMCID: PMC4931768          DOI: 10.1089/dia.2015.0316

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  22 in total

1.  The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Authors:  Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler
Journal:  Pediatr Diabetes       Date:  2008-09-24       Impact factor: 4.866

2.  Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia.

Authors:  Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

3.  Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes.

Authors:  Eleni Z Giannopoulou; Christiane Winkler; Ruth Chmiel; Claudia Matzke; Marlon Scholz; Andreas Beyerlein; Peter Achenbach; Ezio Bonifacio; Anette-G Ziegler
Journal:  Diabetologia       Date:  2015-07-03       Impact factor: 10.122

4.  Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement.

Authors:  C J Greenbaum; J P Palmer; B Kuglin; H Kolb
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

5.  GAD autoantibody affinity in schoolchildren from the general population.

Authors:  Christine Bender; Michael Schlosser; Urs Christen; Anette G Ziegler; Peter Achenbach
Journal:  Diabetologia       Date:  2014-06-18       Impact factor: 10.122

6.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

Authors:  Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

7.  ICA512 autoantibody radioassay.

Authors:  R Gianani; D U Rabin; C F Verge; L Yu; S R Babu; M Pietropaolo; G S Eisenbarth
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

8.  Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).

Authors:  Andrea K Steck; Kendra Vehik; Ezio Bonifacio; Ake Lernmark; Anette-G Ziegler; William A Hagopian; JinXiong She; Olli Simell; Beena Akolkar; Jeffrey Krischer; Desmond Schatz; Marian J Rewers
Journal:  Diabetes Care       Date:  2015-02-09       Impact factor: 17.152

9.  Development of autoantibodies in the TrialNet Natural History Study.

Authors:  Kendra Vehik; Craig A Beam; Jeffrey L Mahon; Desmond A Schatz; Michael J Haller; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer
Journal:  Diabetes Care       Date:  2011-07-12       Impact factor: 19.112

10.  Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Tihamer Orban; Jay M Sosenko; David Cuthbertson; Jeffrey P Krischer; Jay S Skyler; Richard Jackson; Liping Yu; Jerry P Palmer; Desmond Schatz; George Eisenbarth
Journal:  Diabetes Care       Date:  2009-09-09       Impact factor: 17.152

View more
  13 in total

1.  The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.

Authors:  Laura M Jacobsen; Laura Bocchino; Carmella Evans-Molina; Linda DiMeglio; Robin Goland; Darrell M Wilson; Mark A Atkinson; Tandy Aye; William E Russell; John M Wentworth; David Boulware; Susan Geyer; Jay M Sosenko
Journal:  Diabetologia       Date:  2019-11-25       Impact factor: 10.122

Review 2.  Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2018-08-30       Impact factor: 4.810

Review 3.  T1D Autoantibodies: room for improvement?

Authors:  Liping Yu; Zhiyuan Zhao; Andrea K Steck
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-08       Impact factor: 3.243

4.  Islet Autoantibody Detection by Electrochemiluminescence (ECL) Assay.

Authors:  Liping Yu
Journal:  Methods Mol Biol       Date:  2016

Review 5.  B cells in type 1 diabetes mellitus and diabetic kidney disease.

Authors:  Mia J Smith; Kimber M Simmons; John C Cambier
Journal:  Nat Rev Nephrol       Date:  2017-10-17       Impact factor: 28.314

Review 6.  Endotypes in T1D: B lymphocytes and early onset.

Authors:  Mia J Smith; John C Cambier; Peter A Gottlieb
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-08       Impact factor: 3.243

7.  The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.

Authors:  Jay M Sosenko; Liping Yu; Jay S Skyler; Jeffrey P Krischer; Peter A Gottlieb; David Boulware; Dongmei Miao; Jerry P Palmer; Andrea K Steck
Journal:  Diabetes Technol Ther       Date:  2017-02-08       Impact factor: 6.118

8.  Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

Authors:  Alexandra Fouts; Laura Pyle; Liping Yu; Dongmei Miao; Aaron Michels; Jeffrey Krischer; Jay Sosenko; Peter Gottlieb; Andrea K Steck
Journal:  Diabetes Care       Date:  2016-07-25       Impact factor: 19.112

Review 9.  Islet autoantibodies in disease prediction and pathogenesis.

Authors:  Xiaofan Jia; Yong Gu; Hilary High; Liping Yu
Journal:  Diabetol Int       Date:  2019-10-16

10.  Islet Autoantibody Detection by Electrochemiluminescence (ECL) Assay.

Authors:  Yong Gu; Zhiyuan Zhao; Hilary High; Tao Yang; Liping Yu
Journal:  J Clin Cell Immunol       Date:  2017-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.